612 results about "Dysphagia" patented technology

The invention is directed to manufacturing and testing methods of electronic intraoral devices for diagnose, monitor and treat local and systemic diseases and conditions for humans and animals. More specifically, the current invention deals with manufacturing techniques, testing methods and a testing apparatus of mainly three types of intra-oral devices: (a) electro-stimulators for various applications such as treatment of dry mouth by stimulating saliva secretion, apnea, sleeping disorders, eating disorders (obesity, anorexia, etc.) dysphagia and others, (b) drug delivery devices; and (c) bio-sensing and monitoring devices. The common parts or the devices are: (1) art electronic module embedded in the device: (2) or a power source being embedded in the device; (3) the devices (or part of them) being placed in the oral cavity.

A method and system for treating dysphagia using electrical stimulation of a human's or animals's vagus nerve, or recurrent laryngeal nerve, or both to cause glottic or vocal fold motion in humans or animals. Stimulation is caused by utilizing a power source; an external controller for generating and providing an output signal having a given intensity, frequency, and pulse duration; an output protector circuit for limiting the intensity of the output signal; a treatment duration circuit for controlling the duration of operation of the external controller, a ramp control circuit for controlling the intensity of the output signal; and a monitor portion for displaying operating parameters of the device. The external controller regulates the intensity, the frequency, and the pulse duration of the output signal in accordance with a procedure for treating dysphagia.

A novel edible polymer based film dosage form manufactured using natural, synthetic, semisynthetic, pharmaceutically acceptable polymers addressing the issues of swallowing difficulties (Dysphagia and Dynaphagia), of tablet or capsule dosage forms and handling and storage difficulties associated with liquid dosage forms, that also includes materials such as emulsifying agents, suspending agents, buffering agents, effervescence agents, colorants, flavorants, sweeteners and specified amounts of bioactive agents, for erectile dysfunction. A flexible film dosage form containing sildenafil citrate, tadalafil or Vardenafil is presented. The film system is enabled to be used in various applications such as oral, mucosal and external environments.

The invention is drawn to airway implant devices that can alleviate and remediate the effects of dysphagia and aspiration that occur under a wide range of clinical conditions, such as Parkinson's disorder, Alzheimer's disease, or stroke. The devices can further be used to reduce the risk of onset of aspiration pneumonia in these and many other clinical conditions.

A oral-cavity effervescent talbet for treating cardiovascular and cerebrovascular diseases, such as coronary heart disease, angina pectoris, cerebral thrombosis, cerebral infarction, etc. is prepared from breviscapine, diluent, disintegrant, effervescent agent, flavouring, flowing aid,and lubricant.

Stimulation system, comprising an implantable stimulation device (60), at least one implantable stimulation electrode (70) and at least one initializing sensor (40), whereby the initializing sensor (40) is configured to detect in the implanted state a voluntarily controlled muscle movement, a voluntarily induced brainwave or a voluntarily generated nerve pulse of a patient during the initial phase of a swallowing process and to generate a sensor signal in response thereto either continuously or in a clocked cycle or in response to the preceding and to send this signal to the stimulation device (60), and whereby the stimulation device (60) is configured to trigger the delivery of a stimulation pulse via the stimulation electrode (70) in response to such a sensor signal of the initializing sensor (40) which is based on a voluntarily initiated swallowing process.

The present invention relates to thickened beverage compositions. More particularly the invention relates to beverage compositions thickened for the management of dysphagia. More particularly this invention relates to the production of thickened beverages by a dispensing machine that is also capable of dispensing non-thickened beverages.

The invention belongs to the technical field of medicines and relates to an olanzapine orally-disintegrating tablet preparation and a preparation method thereof. The orally-disintegrating tablet comprises the following components in weight percentage: 2.5%-10% of olanzapine, 35%-74% of mannitol, 10%-40% of lactose, 0-10% of dry adhesives, 2.0%-10% of disintegrating agents, 0.1%-6% of flavoring agents and 0.4%-3% of lubricants. A dry-method direct tablet compressing technology and a dry-compressing particle tablet compressing technology can be adopted in the preparation process. The invention aims to provide an olanzapine orally-disintegrating tablet having simple preparation process, low cost, convenient taking and rapid effect taking. After being orally taken, the olanzapine orally-disintegrating tablet is rapidly disintegrated and dispersed into fine particles or powder and is especially suitable for patients with dysphagia and psychopaths; as the preparation exists in a fine particle or powder form before arriving at gastrointestinal tracts, medicines have quickened dissolution, large distribution area in the gastrointestinal tracts and more adsorption points; and for indissoluble medicines, such as the olanzapine, the bioavailability of the indissoluble medicines can be improved.

The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and/or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.

The present invention provides a method in which a quantitative and descriptive approach is used to adapt the food texture in the clinical management of dysphagia. There is provided a new index, ST index, and method of use for determining and modulating the physical characteristics of foods in a manner to allow the food composition at serving temperature to have a desired combination of firmness, adhesiveness, springiness and cohesiveness.

The present invention provides methods of treating or reducing dysphagia in patients. In one aspect of the invention, such method comprises administering to a patient in need of such treatment or reduction an amount of an agent sufficient to produce a therapeutically effective aversive taste response. In other aspects, such methods comprise inducing in a patient in need of such treatment or reduction a therapeutically effective aversive taste response as well as administering to the patient a further swallowing stimulus.

The invention relates to a traditional Chinese medicine medicament for curing insomnia. The prescription of the invention is that wild or spiny jujuba seed 325-975, bupleurum root 190-570, white peony root 190-570, albizia flower 240-720, albizia bark 240-720, batryticated silkworm 150-450, cicada shell 150-450, and rush 15-45 grams. The invention adopts the common methods to prepare miscellaneous medicament types which are capsules, tablets, soft capsules, pelletized granules, oral administration medicaments, pills, dropping pills, externally used immersed medicaments and the like. After the medicament effectiveness test and the clinical test, the medicament is certificated for having the functions of purging the liver of pathogenic fire, relieving depression, and relieving mental stress. The invention is used for curing insomnia which is caused by the depression of liver and the overtaxing of nerves, further the invention cures insomnia and dreamful sleep, mental depression or precipitancy and irascibility, fullness in the chest and hypochondrium or stagnation of the chest dysphagia, and bitter mouth and light-headedness, further the invention cures the symptoms of slightly red tongue border tip, white and slightly yellow tongue coating and wiry pulse essentially. The invention has a relative good curative effect of relieving the fantod and improving the sleeping, and the invention is tested for having a reliable curative effect, thereby the invention can be extensively extended and used.

The invention provides an easily-swallowed drug-loaded microsphere. After the surface of the microsphere enters the oral cavity, a smoothing effect can be achieved by virtue of extremely little water, namely, in a saliva environment, so that the microsphere can quickly enter the esophagus along with swallowing actions, therefore, the microsphere is especially suitable for patients with dysphagia. The drug-loaded microsphere comprises a drug or a drug-loaded mini-pill, the outside surface of the microsphere is coated with a smoothing structure, and in terms of the weight of the drug or the drug-loaded mini-pill, the weight of the smoothing structure is increased by 1-100%; the drug-loaded microsphere has a better protection effect on the stability of the drug, such as preventing outside light, moisture and air from affecting the drug; and the bad smell of the drug can be hidden.

The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a pharmaceutical product for oral administration, comprising the granular composition. The product excellently masks a disagreeable taste possessed by a drug and provides good sensation upon oral administration, and therefore is easily ingested by even the elderly, children, and patients suffering dysphagia. Moreover, the product is suitable for administration using tube.

The invention relates to a brexpiprazole oral fast dissolving film which can be dissolved instantly in the oral cavity and is used for improving a using property of brexpiprazole, and belongs to the field of medicinal preparations. The brexpiprazole oral fast dissolving film includes a medicine active ingredient and auxiliary materials applicable to pharmacy. Brexpiprazole is adopted as the medicine active ingredient. The auxiliary materials applicable to the pharmacy include a film forming material, plasticizer, an absorption enhancer, a flavoring agent and the like. The brexpiprazole oral fast dissolving film has the advantages of being large in drug-loading capacity, small in thickness, good in mouthfeel, capable of being dissolved in the oral cavity instantly without drinking water, and high in oral absorption speed, solves the problems that severe depression patients and schizophrenia patients are poor in medicine taking compliance, hide medicine and vomit the medicine, and is particularly suitable for the patients with dysphagia.

The invention provides an enteral nutrient agent for cancer patients. The total energy of per 100g of the nutrient agent is 1800-2200kJ, and the nutrient agent comprises the following components in parts by weight: 15-25 parts of proteins, 40-50 parts of fat, 10-20 parts of carbohydrate, 5-13 parts of dietary fibers, 4-8 parts of amino acids, 0.05-0.3 part of vitamin complex, 1.8-3.6 parts of mineral complex, 0.5-2 parts of beta-hydroxy-beta-methyl calcium butyrate and 0.11-0.14 part of taurine. The nutrient agent has the characteristics of high fat, high energy and low carbohydrate, and is particularly suitable for patients with cachexia, anorexia, dysmasesis and dysphagia, as well as nutrient support for patients in radiotherapy, chemotherapy and late stage.

A food product that is suitable for an elderly person or a person who has difficulty in chewing or swallowing is obtained by impregnating a material with an enzyme, said food product having a smooth texture and sufficient softness to be crushed by the gums or tongue in the mouth, while maintaining the natural shape and color of the material. The food product has a compressive strength of 5×10⁴ N/m² or lower when measured at a compression rate of 10 mm/sec by using a plunger with a diameter of 3 mm and setting the clearance at 30% of the thickness of the specimen.

The present invention relates to a small particle size composition comprising pancreatin containing digestive enzymes for use in patients in need, including pediatric, geriatric, and adult patients, particularly those patients with dysphagia or wherein enteral administration using such composition would be suitable. In addition, the invention is directed to the composition as particles, such as micropellets or microgranules having a high potency, high useable yield and at least 10%-90% of 400-800 μm. Furthermore, the composition optionally has an improved enteric coating and concomitant improved stability and enzyme activity compared to conventional prepared enterically coated pancreatic enzyme particles.

The nanometer emulsion oral liquid of andrographolide consists of surfactant, oil, andrographolide and distilled water. Its preparation process includes the following steps:weighing surfactant with or without co-surfactant; calculating HLB value and selecting oil for reaching emulsifying HLB value near that of the surfactant phase; changing the ratio between the surfactant phase and the oil phase regularly to dissolve andrographolide in the surfactant; adding distilled water slowly at 20-25 deg.c to form clear and flowing O/W type stable nanometer emulsion oral liquid. The nanometer emulsion oral liquid has high dissolubility of andrographolide, raised bioavailability of andrographolide, less stimulation to gastrointestinal tract and raised patient's compliance, and may be also taken easily by children and persons with dysphagia.